ST Pharm Co.,Ltd. (KOSDAQ: 237690)

Market Cap	1.92T
Revenue (ttm)	272.89B
Net Income (ttm)	21.71B
Shares Out	19.88M
EPS (ttm)	1,151.15
PE Ratio	84.09
Forward PE	40.47
Dividend	500.00 (0.50%)
Ex-Dividend Date	n/a

Volume	221,328
Open	101,400
Previous Close	99,500
Day's Range	99,900 - 103,600
52-Week Range	59,900 - 120,800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About ST Pharm Co.,Ltd.

ST Pharm Co.,Ltd., provides custom manufacturing services for active pharmaceutical ingredient and intermediates in South Korea and internationally. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical R and D solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co....

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1983
• Employees: 665
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2023, ST Pharm Co.,Ltd.'s revenue was 284.99 billion, an increase of 14.31% compared to the previous year's 249.32 billion. Earnings were 19.58 billion, an increase of 8.78%.